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FPIN's Clinical Inquiries 
Vaginal Misoprostol for Cervical Ripening in Term Pregnancy 
Clinical Question 
How safe and effective is vaginal misoprostol (Cytotec) for cervical ripening in a term 
pregnancy? 
Evidence-Based Answer 
Low-dose (25 mcg) intravaginal misoprostol appears to be safe and effective for cervical 
ripening in term pregnancy for patients without a history of cesarean section. Compared with 
other cervical ripening methods, misoprostol has an increased rate of vaginal delivery within 24 
hours without significant differences in cesarean section rates or fetal outcomes. (Strength of 
recommendation: B, systematic review of randomized controlled trials) 
A 50-mcg dose of intravaginal misoprostol causes increased rates of uterine hyperstimulation 
and may be associated with an increased cesarean section rate. (Strength of recommendation: B, 
single prospective randomized controlled trial) 
Because of a potential increased risk of uterine rupture, use of misoprostol for labor induction in 
women with a previous cesarean section is relatively contraindicated. (Strength of 
recommendation: B, large population-based retrospective cohort study) 
Evidence Summary 
Cervical ripening is a process that is intended to soften, dilate, and efface the cervix. An unripe 
cervix is generally not yet soft, is dilated less than 2 cm, and is less than 50 percent effaced. 
Procedures that ripen the cervix commonly are used in routine pregnancies (with an unripe 
cervix) that extend past 41 weeks or when complications dictate a delivery before the mother 
spontaneously goes into labor. Misoprostol is a synthetic prostaglandin E1 analogue commonly 
used for cervical ripening and labor induction; however, it is not approved by the U.S. Food and 
Drug Administration for this purpose. A recent Cochrane systematic review1 of 70 studies, 13 of 
which were blinded, examined the use of vaginal misoprostol for cervical ripening and labor 
induction. Subgroup analysis of vaginal misoprostol versus other vaginal prostaglandins and 
versus intracervical prostaglandins found more patients delivering vaginally within 24 hours 
when misoprostol was used (>17 trials, number needed to treat [NNT] = 10).1 Cesarean section 
rates for patients receiving vaginal misoprostol and other vaginal/intracervical prostaglandins 
varied between studies, but no significant overall difference was found (38 trials).1 This same 
review1 reported that low-dose (25 mcg) misoprostol is associated with more need for oxytocin 
(Pitocin) augmentation (13 trials, relative risk [RR], 1.23; 95% confidence interval [CI], 1.08 to 
1.40; number needed to harm [NNH] = 11) but results in less uterine hyperstimulation compared 
with 50-mcg doses (RR, 0.61; 95% CI, 0.49 to 0.76; NNT = 25). There also was a trend to fewer 
neonatal intensive care unit (NICU) admissions with lower doses compared with higher doses of 
intravaginal misoprostol. 
In another systematic review of five high-quality randomized controlled trials involving 933 
women,2 there were no significant differences between 25- and 50-mcg misoprostol dose groups 
with respect to cesarean section rates (19.1 and 18.9 percent, respectively) or operative vaginal 
delivery. No dose-related differences were found with respect to abnormal Apgar scores, 
admissions to the NICU, or patients requiring cesarean section for fetal heart rate abnormalities. 
Oxytocin augmentation was used more often in the 25-mcg dose group (29 versus 13.2 percent). 
The 50-mcg dose did result in a faster time to vaginal delivery (five hours shorter)2 but was 
associated with a higher incidence of uterine hyperstimulation (20.8 versus 8.9 percent in the 25-
mcg dose group). 
A more recent, high-quality, prospective double-blind randomized controlled study3 of 114 
subjects comparing 25 versus 50 mcg of intravaginal misoprostol reported a significantly higher 
cesarean section rate with a 50-mcg dose of misoprostol (28.6 versus 10.3 percent; NNH = 6). 
This primarily was caused by abnormal fetal heart rate patterns. Oxytocin augmentation was 
required less often with 50 mcg of misoprostol (32.1 versus 63.8 percent; NNT = 4), but the rate 
of oxytocin use was still much higher than shown in the previously mentioned review.2 The 
impact this had on the cesarean section rate was not explored. 
One small (68 patients) randomized, double-blind, placebo-controlled trial4 recently reported 
that a single 25-mcg outpatient dose of misoprostol significantly decreased the interval to 
delivery compared with placebo (4.1 versus 9.2 days; P = .04). 
Finally, a large, population-based, retrospective cohort analysis5 of more than 20,000 births 
demonstrated that induction of labor with prostaglandins (including misoprostol) among women 
with a previous cesarean section delivery is associated with an increased risk of uterine rupture 
(RR, 15.6; 95% CI, 8.1 to 30.0). 
The published data appear to indicate that intravaginal misoprostol is safe and effective. Cervical 
ripening and subsequent labor induction is probably more effective with the 50-mcg dose; 
however, the currently available information reveals conflicting data on whether the higher dose 
is as safe as the 25-mcg dose. 
Recommendations from Others 
The American College of Obstetricians and Gynecologists recommends that low-dose 
misoprostol (25 mcg every three to six hours) is effective for cervical ripening but should not be 
used in women with previous cesarean delivery because of increased rates of uterine rupture.6 A 
practice recommendation from the American Academy of Family Physicians supports the safety 
and effectiveness of vaginal misoprostol for cervical ripening and labor induction.7 
Clinical Commentary 
Methods for cervical ripening with subsequent labor induction at term vary greatly by physician 
and practice locale. Vaginal misoprostol appears to be well tolerated by patients and is a cost-
effective alternative to intravaginal/intracervical prostaglandins. Misoprostol costs a few dollars 
for multiple doses compared with several hundred dollars per dose for an intracervical 
prostaglandin preparation such as dinoprostone (Cervidil). Vaginal misoprostol can be used 
effectively by family physicians either as a cervical ripening agent or for labor induction. 
Additionally, because vaginal misoprostol does not require connecting a patient to an 
intravenous line, patients may be more comfortable as they are able to move around more freely 
during labor. In summary, low-dose (25 mcg) intravaginal misoprostol appears to be safe and 
effective for cervical ripening in term pregnancy for women without a history of cesarean 
section. 
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